Companies › Life Biosciences
1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ER-100 AAV-based epigenetic therapy delivering OSK transcription factors (OCT4, SOX2, KLF4) via i | OCT4, SOX2, KLF4 | Phase 1 | Open Angle Glaucoma (OAG) | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07290244 | ER-100 | Phase 1 | Open Angle Glaucoma (OAG) | Ophthalmology | May 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.